Article Text

other Versions

Download PDFPDF
Mitoxantrone as induction treatment in aggressive relapsing remitting Multiple Sclerosis: treatment response factors in a 5-year follow-up observational study of 100 consecutive patients
  1. Le Page Emmanuelle, E. (emmanuelle.lepage{at}
  1. CHU Pontchaillou , RENNES, France
    1. Leray Emmanuelle, E. (manuetguillaume{at}
    1. CHU Pontchaillou , RENNES, France
      1. Taurin Grégory, G. (taurin.greg{at}
      1. CHU Pontchaillou , RENNES, Grenada
        1. Coustans Marc M. (m.coustans{at}
        1. CHU Pontchaillou , RENNES, Gibraltar
          1. Chaperon Jacques, J. (jacques.chaperon{at}
          1. CHU Pontchaillou, RENNES, France
            1. Morrissey Sean, S.P. (sean.morrissey{at}
            1. CHU Pontchaillou, RENNES, France
              1. Edan Gilles, G. (gilles.edan{at}
              1. CHU Pontchaillou, RENNES, France


                Background: Mitoxantrone was approved by the French health authority (AFSAPPS) in October 2003 to treat patients with aggressive multiple sclerosis (MS).

                Objective: To report long-term effectiveness and safety of Mitoxantrone as induction therapy in Aggressive Relapsing Remitting MS patients and to assess treatment response factors.

                Material and methods: 100 consecutive aggressive relapsing-remitting MS patients received Mitoxantrone 20 mg monthly combined with methylprednisolone 1g for 6 months. Relapses, EDSS and drug safety were assessed every 6 months up to at least 5 years. Within 6 months after induction, 73 patients received a maintenance therapy (Mitoxantrone every 3 months: 21; Interferon beta: 25; Azathioprine: 15; Methotrexate: 7; Glatiramer acetate: 5).

                Results: During the 12 months following Mitoxantrone start, the Annual Relapse Rate (ARR) was reduced by 91%, 78% of patients remained relapse-free, MRI activity was reduced by 89%, the mean EDSS decreased by 1.2 points (p<10-6) and 64% of patients improved by 1 point EDSS or more. At a longer term, the ARR reduction was sustained (0.29-0.42 up to 5 years), the median time to the first relapse was 2.8 years and disability remained improved up-to 5 years. Younger age and lower EDSS at Mitoxantrone start were predictive of better treatment response. Three patients presented an asymptomatic decrease of the left ventricular ejection fraction under 50% (1 reversible). One patient was diagnosed with acute myeloid leukemia (remission 5 years after diagnostic).

                Conclusion: Mitoxantrone monthly for 6 months as induction therapy followed by a maintenance treatment showed sustained clinical benefit up to 5 years with acceptable adverse events profile in patients with aggressive relapsing-remitting MS.

                • Aggressive Relapsing remitting
                • Drug safety
                • Immunosuppression
                • Mitoxantrone
                • Multiple sclerosis

                Statistics from

                Request Permissions

                If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.